Cargando…

In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020

The objective of this study was to assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates causing skin and soft tissue infections (SSTIs) collected in Africa/Middle East, Asia–Pacific, Europe, and Latin America from 2019–2020. Minimum inhibitory concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuraieva, Alona, Cabezas-Camarero, Guillermo, Kiratisin, Pattarachai, Utt, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451970/
https://www.ncbi.nlm.nih.gov/pubmed/37627657
http://dx.doi.org/10.3390/antibiotics12081237
_version_ 1785095551031705600
author Kuraieva, Alona
Cabezas-Camarero, Guillermo
Kiratisin, Pattarachai
Utt, Eric
author_facet Kuraieva, Alona
Cabezas-Camarero, Guillermo
Kiratisin, Pattarachai
Utt, Eric
author_sort Kuraieva, Alona
collection PubMed
description The objective of this study was to assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates causing skin and soft tissue infections (SSTIs) collected in Africa/Middle East, Asia–Pacific, Europe, and Latin America from 2019–2020. Minimum inhibitory concentrations (MIC) were determined using European Committee on Antimicrobial Susceptibility Testing criteria. All the methicillin-susceptible Staphylococcus aureus (MSSA) isolates were susceptible to ceftaroline. Across all regions, ceftaroline demonstrated potent activity against methicillin-resistant S. aureus (MRSA, susceptibility 89.5–93.7%) isolates. Susceptibility to vancomycin, daptomycin, linezolid, teicoplanin, trimethoprim sulfamethoxazole, and tigecycline was ≥94.1% in MSSA and MRSA isolates. Against β-hemolytic streptococci isolates, ceftaroline demonstrated very potent activity (MIC(90) 0.008–0.03 mg/L) across all regions. All β-hemolytic streptococci isolates were susceptible to linezolid, penicillin, and vancomycin (MIC(90) 0.06–2 mg/L). Among the extended-spectrum β-lactamases (ESBL)-negative Enterobacterales tested (E. coli, K. pneumoniae, and K. oxytoca), susceptibility to ceftaroline was high (88.2–98.6%) in all regions. All ESBL-negative Enterobacterales were susceptible to aztreonam. Potent activity was observed for amikacin, cefepime, and meropenem (94.1–100%) against these isolates. Overall, ceftaroline showed potent in vitro activity against isolates of pathogens causing SSTIs. Continuous surveillance of global and regional susceptibility patterns is needed to guide appropriate treatment options against these pathogens.
format Online
Article
Text
id pubmed-10451970
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104519702023-08-26 In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020 Kuraieva, Alona Cabezas-Camarero, Guillermo Kiratisin, Pattarachai Utt, Eric Antibiotics (Basel) Article The objective of this study was to assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates causing skin and soft tissue infections (SSTIs) collected in Africa/Middle East, Asia–Pacific, Europe, and Latin America from 2019–2020. Minimum inhibitory concentrations (MIC) were determined using European Committee on Antimicrobial Susceptibility Testing criteria. All the methicillin-susceptible Staphylococcus aureus (MSSA) isolates were susceptible to ceftaroline. Across all regions, ceftaroline demonstrated potent activity against methicillin-resistant S. aureus (MRSA, susceptibility 89.5–93.7%) isolates. Susceptibility to vancomycin, daptomycin, linezolid, teicoplanin, trimethoprim sulfamethoxazole, and tigecycline was ≥94.1% in MSSA and MRSA isolates. Against β-hemolytic streptococci isolates, ceftaroline demonstrated very potent activity (MIC(90) 0.008–0.03 mg/L) across all regions. All β-hemolytic streptococci isolates were susceptible to linezolid, penicillin, and vancomycin (MIC(90) 0.06–2 mg/L). Among the extended-spectrum β-lactamases (ESBL)-negative Enterobacterales tested (E. coli, K. pneumoniae, and K. oxytoca), susceptibility to ceftaroline was high (88.2–98.6%) in all regions. All ESBL-negative Enterobacterales were susceptible to aztreonam. Potent activity was observed for amikacin, cefepime, and meropenem (94.1–100%) against these isolates. Overall, ceftaroline showed potent in vitro activity against isolates of pathogens causing SSTIs. Continuous surveillance of global and regional susceptibility patterns is needed to guide appropriate treatment options against these pathogens. MDPI 2023-07-26 /pmc/articles/PMC10451970/ /pubmed/37627657 http://dx.doi.org/10.3390/antibiotics12081237 Text en © 2023 by Pfizer Inc. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuraieva, Alona
Cabezas-Camarero, Guillermo
Kiratisin, Pattarachai
Utt, Eric
In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
title In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
title_full In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
title_fullStr In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
title_full_unstemmed In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
title_short In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019–2020
title_sort in vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin and soft tissue infections: atlas program 2019–2020
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451970/
https://www.ncbi.nlm.nih.gov/pubmed/37627657
http://dx.doi.org/10.3390/antibiotics12081237
work_keys_str_mv AT kuraievaalona invitroactivityofceftarolineandcomparatorsagainstbacterialisolatescollectedgloballyfrompatientswithskinandsofttissueinfectionsatlasprogram20192020
AT cabezascamareroguillermo invitroactivityofceftarolineandcomparatorsagainstbacterialisolatescollectedgloballyfrompatientswithskinandsofttissueinfectionsatlasprogram20192020
AT kiratisinpattarachai invitroactivityofceftarolineandcomparatorsagainstbacterialisolatescollectedgloballyfrompatientswithskinandsofttissueinfectionsatlasprogram20192020
AT utteric invitroactivityofceftarolineandcomparatorsagainstbacterialisolatescollectedgloballyfrompatientswithskinandsofttissueinfectionsatlasprogram20192020